Synthorx, spun out of Scripps Research Institute, is targeting $100m in a proposed offering half a year after it raised $63m in a series C round backed by Osage University Partners.

The biopharmaceutical spinout of University of Veterinary Medicine Vienna is issuing 400,000 shares in an initial public offering that is set to fetch between $34m and $41m.

The Kaiser Permanente-backed medical device producer upscaled its initial public offering to $64.4m after the underwriters took up the over-allotment option.

The Hakim Unique, Shanda Interactive and Dong Yi Ri Sheng-backed lending platform raised $45m, floating in the middle of its range.

Utec-backed Chiba spinout Autonomous Control Systems Laboratory has filed for an initial public offering on the Tokyo Stock Exchange and plans to list on December 21.

Kaiser Permanente-backed respiratory device provider Vapotherm floated at the bottom of its range but raised $56m in its initial public offering.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

Illumina, WuXi PharmaTech, Kangmei and Institut Mérieux-backed synthetic DNA producer Twist Bioscience floated at the bottom of its range.

UCL Technology Fund-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.

GSK, Sphera Global and Medison-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.